A selective irreversible inhibitor targeting a PDZ protein interaction domain
Naoaki Fujii1, Jose J Haresco, Kathleen A P Novak
1Department of Pharmaceutical Chemistry, University of California at San Francisco, Genentech Hall, Mission Bay, 600 16th Street 2280, San Francisco, California 94143-2280, USA.
Journal of the American Chemical Society
|October 2, 2003
Summary
Researchers developed a novel irreversible inhibitor targeting protein interactions, specifically the MAGI3 PDZ domain. This breakthrough enables studying protein-protein interactions and releases PTEN, upregulating the PKB pathway.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Irreversible protease inhibitors are valuable tools for studying enzyme activity and function.
- Designing irreversible inhibitors for protein-protein interactions, particularly targeting specific domains like PDZ, has been challenging due to a lack of mechanistic principles.
Purpose of the Study:
- To report the first mechanism-based irreversible inhibitor targeting a specific protein interaction, focusing on the second PDZ domain of MAGI3.
- To demonstrate the inhibitor's utility in studying the interaction between PTEN and MAGI3 and its downstream effects on cellular signaling.
Main Methods:
- Rational design of an irreversible inhibitor using computational evaluation, exploiting a conserved histidine residue in the MAGI3 PDZ domain.
- In vitro assays to characterize the inhibitor's properties and its effect on the PTEN-MAGI3 interaction.
- Cell-based experiments to assess the inhibitor's impact on PTEN release and PKB signaling pathway activation.
Main Results:
- A novel irreversible inhibitor was successfully designed and synthesized, targeting the MAGI3 PDZ domain.
- The compound demonstrated irreversible inhibition of the PTEN-MAGI3 interaction in vitro.
- In cellular models, the inhibitor released PTEN from MAGI3 and led to the upregulation of the PKB signaling pathway.
Conclusions:
- This study presents the first mechanism-based irreversible inhibitor for a protein interaction, specifically targeting the MAGI3 PDZ domain.
- The developed inhibitor serves as a powerful tool for dissecting the functional role of the PTEN-MAGI3 interaction in physiological processes.
- The findings open new avenues for therapeutic strategies by modulating protein-protein interactions and associated signaling pathways.
Related Concept Videos
00:46Feedback Inhibition
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...